The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for growth at lower price points. While often associated with smaller or newer companies, these stocks can offer potential upside when backed by strong fundamentals and sound balance sheets.

Let's explore several standout options from the results in the screener.

Identiv (INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. develops, manufactures, and supplies specialty IoT products across various regions including the United States, Europe, the Middle East, and Asia-Pacific with a market cap of $100.58 million.

Operations: Identiv, Inc. has not reported any specific revenue segments.

Market Cap: $100.58M

Identiv, Inc. has shown potential in the penny stock arena with its recent launch of ID-Pixels 3.0, enhancing supply chain capabilities through advanced IoT technology. Despite being unprofitable and experiencing increased losses over five years, Identiv's debt-free status and substantial short-term assets exceeding liabilities provide financial stability. The company reported first-quarter sales of US$7.41 million, an improvement from the previous year, although net losses persist at US$3.45 million for the quarter. With a seasoned management team and sufficient cash runway for over three years, Identiv is positioned to leverage its innovative product offerings while navigating profitability challenges.

ProKidney (PROK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States, with a market cap of $522.56 million.

Operations: ProKidney generates its revenue from its Biotechnology (Startups) segment, amounting to $0.89 million.

Market Cap: $522.56M

ProKidney Corp., a clinical-stage biotechnology company, remains pre-revenue with sales under US$1 million, highlighting its early-stage status. The recent appointment of Kenneth Locke as Chief Technical Officer and Greg Madison as Chief Commercial Officer strengthens the company's leadership team as it advances towards potential commercialization of rilparencel. Despite being unprofitable with increasing losses over five years, ProKidney's short-term assets significantly exceed its liabilities, ensuring financial stability without debt. With revenue forecasted to grow substantially and sufficient cash runway for over a year, ProKidney is poised for growth while addressing profitability challenges in the biotech sector.

Here Group (HERE)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Here Group Limited designs and sells pop toys in China, with a market capitalization of approximately $119.10 million.

Operations: The company generates revenue primarily from its operations in the People's Republic of China, amounting to CN¥1.49 billion.

Market Cap: $119.1M

Here Group Limited, with a market cap of US$119.10 million, operates primarily in China’s pop toy sector. Recent earnings show sales of CN¥164.74 million for Q3 2026 but a net loss of CN¥34.14 million, reflecting challenges in profitability and declining profit margins from last year’s 12% to 6.6%. Despite this, the company maintains strong liquidity with short-term assets exceeding liabilities and more cash than debt, supporting financial stability. The announcement of a US$20 million share buyback program could indicate confidence in its valuation as it trades significantly below fair value estimates despite negative earnings growth recently.

Seize The Opportunity

• Investigate our full lineup of 331 US Penny Stocks right here.
• Interested In Other Possibilities? Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.